New combo therapy aims to halt prostate cancer spread in high-risk patients

NCT ID NCT07237269

Recruiting now Disease control Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated May 13, 2026 · Updated 24 times

Summary

This study is for men with prostate cancer that has spread to pelvic lymph nodes only detectable by a special PSMA-PET scan. It compares standard hormone therapy plus radiation to a stronger combination that includes abiraterone and prednisone. The goal is to see if the stronger therapy improves survival without cancer progression over 5 years. About 140 participants will be randomly assigned to one of the two treatment groups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER